Vnitr Lek 2015, 61(4):316-319

Treatment of GLP1 receptor agonists and body mass control

Petr Žák^*, Jindřich Olšovský

Diabetologické centrum II. interní kliniky LF MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.

The prevalence of obesity continues to be increasing in all age groups in most countries of the European Union (EU). Many obese people have a history of several successful weight losses, but very few are able to maintain the weight loss over a longer period of time. Initiation of the GLP1 RA administration during weight loss maintenance would inhibit weight loss-induced increases in soluble leptin receptor plasma concentrations resulting in higher level of free leptin thereby preventing weight regain. In contrast initiation of insulin treatment in type 2 diabetes patients is frequently accompanied with weight gain. The GLP1 administration results in HbA_1c decrease accompanied with weight loss, presents attractive alternative to basal insulin. The question remains to be answered in the future, if the GLP1 RA administration is generally more frequently started in antiobese than antidiabetes implication.

Keywords: agonists of the GLP1 receptor; diabetes mellitus; obesity

Received: February 17, 2015; Accepted: March 13, 2015; Published: April 1, 2015  Show citation